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RESEARCH ARTICLE
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Abstract
Objectives
To assess the association of smoking habits with the clinical, serological, and histopatholog-
ical manifestations of Sjo¨gren’s syndrome (SS) and non-Sjo¨gren’s sicca (non-SS sicca).
Methods
Cross-sectional case-control study of 1288 patients with sicca symptoms (587 SS and 701
non-SS sicca) evaluated in a multi-disciplinary research clinic. Smoking patterns were
obtained from questionnaire data and disease-related clinical and laboratory data were
compared between current, past, ever, and never smokers.
Results
Current smoking rates were 4.6% for SS patients compared to 14.1% in non-SS sicca
(p = 5.17x10E-09), 18% in a local lupus cohort (p = 1.13x10E-14) and 16.8% in the com-
munity (p = 4.12x10E-15). Current smoking was protective against SS classification (OR
0.35, 95%CI 0.22–0.56, FDR q = 1.9E10-05), focal lymphocytic sialadenitis (OR 0.26,
95%CI 0.15–0.44, FDR q = 1.52x10E-06), focus score 1 (OR 0.22, 95%CI 0.13–0.39,
PLOS ONE | DOI:10.1371/journal.pone.0170249 February 6, 2017 1 / 18
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Stone DU, Fife D, Brown M, Earley KE,
Radfar L, Kaufman CE, et al. (2017) Effect of
Tobacco Smoking on The Clinical,
Histopathological, and Serological Manifestations
of Sjo¨gren’s Syndrome. PLoS ONE 12(2):
e0170249. doi:10.1371/journal.pone.0170249
Editor: Masataka Kuwana, Nippon Medical School,
JAPAN
Received: September 7, 2016
Accepted: December 31, 2016
Published: February 6, 2017
Copyright: © 2017 Stone et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: De-identified data is
available within the limits offered to study
participants by the governing institutional review
and privacy boards. Data are available from the
Oklahoma Medical Research Foundation
Institutional Review Board for researchers who
meet the criteria for access to confidential data.
Contact information: Janice Gales, RN, BSN, MS,
CCRP, CIP. IRB Administrator. IRB@omrf.org.
Funding: This work was supported in part by
National Institutes of Health [grant numbers
FDR q = 1.43x10E-07), and anti-Ro/SSA(+) (OR 0.36, 95%CI 0.2–0.64, FDR q = 0.0009);
ever smoking was protective against the same features and against anti-La/SSB(+) (OR
0.52, 95%CI 0.39–0.70, FDR q = 5.82x10E-05). Duration of smoking was inversely corre-
lated with SS even after controlling for socioeconomic status, BMI, alcohol and caffeine
consumption.
Conclusions
Current tobacco smoking is negatively and independently associated with SS, protecting
against disease-associated humoral and cellular autoimmunity. The overall smoking rate
amongst SS patients is significantly lower than in matched populations and the effects of
smoking are proportional to exposure duration.
In spite of the protective effects of tobacco on SS manifestations, it is associated with
other serious comorbidities such as lung disease, cardiovascular risk and malignancy, and
should thus be strongly discouraged in patients with sicca.
Introduction
Tobacco use creates a tremendous burden on the health care system and is the largest non-
communicable source of disease globally; annual tobacco-attributable deaths surpassed 5 mil-
lion in 2010.[1, 2] Cigarette smoking has wide-ranging effects on the user depending on both
extrinsic and intrinsic factors, with a well-described influence on oncogenesis, pulmonary
function, vascular health, and immune response. [3–10] The mechanisms of disease may be as
diverse as the contents of cigarette smoke; carbon monoxide, cyanide, nicotine, benzene, form-
aldehyde, methanol, ammonia, tar and nearly 4000 other chemicals identified in cigarette
smoke.[11]
The dysregulation of immune and inflammatory responses caused by tobacco results in the
association of smoking with various conditions that have inflammatory or autoimmune mech-
anisms as part of their pathophysiology.[9] Perhaps the best examples of associations of cur-
rent tobacco smoking with increased incidence or severity of disease are with rheumatoid
arthritis,[7, 8, 12–15] Crohn’s disease,[16] and multiple sclerosis.[17] The underlying mecha-
nisms that have been postulated for this exacerbated inflammatory or autoimmune response
include hypoxia and oxidative stress,[18] induction of pro-inflammatory cytokines and auto-
antibodies,[9] and epigenetic changes.[19]
However, despite leukocytosis and increases in markers of inflammation such as C-reactive
protein in chronic smokers, there is impairment of some aspects of immune function and
increased susceptibility to certain infections.[10] In some conditions, such as ulcerative colitis,
[16] Behc¸et’s disease,[20] and sarcoidosis,[21] there is a negative correlation between smoking
and disease activity or diagnosis. It is likely that specific gene-environment interactions for
each disease are determinant in the effect that smoking exerts on the phenotype of inflamma-
tory conditions.[8]
Second in prevalence among the rheumatic autoimmune diseases,[22] Sjo¨gren’s syndrome
(SS) is a chronic, systemic disease with a prototypical clinical presentation of xerostomia and
xerophthalmia, associated with immune mediated dysfunction of the salivary and lacrimal
glands.[23] Hallmarks of the autoimmune nature of SS are characteristic lymphocytic infil-
trates of the salivary and lacrimal glands and the presence of circulating autoantibodies, mainly
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anti-Ro/SSA and anti-La/SSB,[24] as well as genetic association to genes involved in innate
and adaptive immunity.[25] In addition to exocrine gland dysfunction, patients with SS have
increased risk of cardiovascular disease,[26] interstitial lung disease and COPD,[27] and a ~20
times higher risk of B cell lymphoma.[23, 28] Few studies have evaluated the role of tobacco
smoking in SS, a relevant consideration given the comorbidities of SS.
A decreased smoking rate in SS has previously been documented but detailed analysis of
tobacco effects on SS manifestations is incomplete. Karabulut, et al.[29] reported a decreased
prevalence of current smoking amongst SS patients in comparison to healthy controls but no
association between smoking and autoantibodies, focus score, or extraglandular involvement.
[29] Nilsson, et al. also found a significantly lower prevalence of smoking amongst SS patients
assessed for COPD when compared to non-SS controls; interestingly, the non-smoking status
of the SS patients was not protective against obstructive and possibly restrictive pulmonary
disease.[27] Two European studies evaluating cardiovascular disease risk in SS reported low
smoking rates,[26, 30] and an inverse correlation of current smoking with presence of anti-Ro/
SSA and anti-La/SSB autoantibodies.[26] Finally, Manthorpe and colleagues[31] did not find
differences in the smoking habits of SS and healthy individuals but determined that smoking at
the time of minor salivary gland (MSG) lip biopsy was associated with lower risk of abnormal
focus score and, to a lesser degree, with absence of circulating anti-Ro/SSA and anti-La/SSB
autoantibodies.
Given the observed effect of tobacco smoking on the clinical manifestations of other auto-
immune conditions and its association with conditions that disproportionately affect patients
with SS, we sought to explore the effects of tobacco use on a carefully characterized population
of patients with SS.
Patients and Methods
Study Participants and Ethical Considerations
The study subjects were 1288 voluntary participants in the Sjo¨gren’s Research Clinics (SRC) at
the Oklahoma Medical Research Foundation (n = 1007), the University of Minnesota (n = 214),
Cedars-Sinai Medical Center (n = 57), and the Carolinas Medical Center (n = 10). Each institu-
tion’s Institutional Review Board approved all procedures and the participants provided two-
tiered informed consent prior to entering the study. Initial verbal consent was obtained before
the screening phone interview and the mailing of study paperwork and questionnaires; on the
day of the clinic visit and before any procedure took place, additional written informed consent
was obtained.
Clinical Procedures
The protocols for patient recruitment, assessment, and data collection have been described
previously[32] and include all the tests necessary for SS classification based on the American-
European Consensus Group 2002 revised criteria[24].
Briefly, candidates for evaluation at the SRC were referred by health care providers or
responded to public advertisement; they included patients already clinically diagnosed with SS
and subjects with subjective dry eyes and dry mouth without a prior diagnosis of the disease.
After explaining the objectives and methods of the study and obtaining verbal consent, trained
personnel assessed the presence of ocular and oral symptoms using a validated telephone ques-
tionnaire and determined eligibility. Exclusion criteria followed the AECG classification[24]
and included past head and neck irradiation, hepatitis C infection, acquired immunodefi-
ciency syndrome, pre-existing lymphoma, sarcoidosis, and graft-versus-host disease as well as
pregnancy and inability to provide informed consent. Additional exclusion criteria for this
Tobacco Effects on Sjo¨gren’s Syndrome
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study were documented overlapping autoimmune conditions; thus, we only included in the
analysis subjects that met criteria for primary SS or non-SS sicca. Use of anticholinergic medi-
cations was not considered as a factor for exclusion, but was documented.
The study subjects participated in multi-specialty clinical evaluation that included oral
examination with measurement of whole unstimulated salivary flow (WUSF), minor salivary
gland lip biopsy, and collection and storage of saliva. The ocular examination included slit
lamp biomicroscopy, Schirmer’s I testing, calculation of the van Bijsterveld (vBS)[33] and ocu-
lar staining scores (OSS)[34] by staining of the cornea with fluorescein and the conjunctiva
with lissamine green, and collection and storage of tears. Blood samples were taken for deter-
mination of relevant autoantibodies as well as extraction of DNA, RNA, and serum for other
studies[32]. A physician with expertise in rheumatological diseases completed a detailed his-
tory and physical examination. If the patient reported a past or current diagnosis of another
autoimmune condition, such as rheumatoid arthritis, mixed connective tissue disease, sys-
temic sclerosis, myositis, primary biliary cirrhosis, multiple sclerosis, or systemic lupus erythe-
matosus (SLE), classification criteria for these illnesses were specifically addressed by history,
review of medical records, and directed diagnostic testing for the corresponding condition.
The histopathologic pattern of the salivary gland biopsy was determined according to the
definitions by Daniels et al[35]:
1. Focal Lymphocytic Sialadenitis: presence of 1 or more dense aggregates of 50 or more lym-
phocytes (usually several hundred or more), usually located in perivascular or periductal loca-
tions. The foci are located adjacent to normal- appearing mucous acini in gland lobes or lobules
lacking duct dilation or interstitial fibrosis and contain no more than a minority proportion of
plasma cells. This diagnosis is assigned when these foci are the only inflammation present in a
specimen, or the most prominent feature. Focus scores are then assigned by assessing the glan-
dular area in each and calculating the number of lymphocytic foci present, per 4 mm2 of glan-
dular area.
2. Non-specific Chronic Inflammation (Sialadenitis): scattered or focal infiltrates of lym-
phocytes, macrophages, and plasma cells that are not adjacent to normal-appearing acini and
located in gland lobules that exhibit some combination of acinar atrophy, interstitial fibrosis,
duct dilation, and luminal inspissated mucus.
3. Sclerosing Chronic Sialadenitis: An advanced stage of nonspecific chronic sialadenitis
in which interstitial fibrosis, various patterns of chronic inflammation, and acinar atrophy
predominate.
4. Within Normal Limits: diagnosed in minor salivary glands with normal-appearing archi-
tecture and scattered plasma cells, but without acinar atrophy and few if any lymphocytes.
5. Granulomatous Inflammation: Clusters of CD-68 positive macrophages, with or without
occasional multinucleated giant cells and without necrosis.
Information about cigarette smoking was collected using a questionnaire mailed to the par-
ticipants before attendance to the SRC. The questions about smoking addressed current or
past smoking, age of onset, and duration of regular smoking. Questions about the number of
cigarettes smoked on average were only added to the questionnaire in the last 18 months, so
the data are not available for the majority of the study participants (S1 Appendix). Unanswered
or incomplete questions were completed at the time of clinic participation with the help of a
trained clinical coordinator. Smoking behaviors were defined as four categories: subjects
reporting to be smokers at the time of study participation were classified as current smokers,
those that reported a history of smoking but had quit were defined as past smokers while sub-
jects that responded they had not been smokers were named never smokers. Ever smokers
were defined as past plus current smokers. For each case, the time of the first diagnosis of SS or
sicca syndrome (prior clinical diagnosis by referring physician or classification resulting from
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SRC evaluation) was considered in order to establish the temporal relation between smoking
and disease. Multiple potential confounding variables were also assessed and detailed informa-
tion can be found in the supplemental materials (S1 Appendix).
The comparison groups included a SLE cohort from the same institution with a similar geo-
graphic, age, and gender distribution,[36, 37] and community smoking prevalence data from
the Centers for Disease Control (CDC),[38] also selected to match the age and gender distribu-
tion of the study cohort.
Statistical Analysis
Count data were analyzed using Fisher’s exact, Pearson’s χ2, or Mann Whitney tests, as appro-
priate. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using the maxi-
mum likelihood estimator (MLE) where applicable. The comparison of smoking prevalence
in SS patients to the community data was done using a proportions (z) test. Comparisons of
AECG criteria between current-past smokers and ever-never smokers were adjusted using the
false discovery rate (FDR) method to correct for multiple testing. Path analysis, logistic regres-
sion models, and Random Forest algorithms[39] were used to estimate the marginal effect of
smoking on SS after controlling for potential confounding variables (detailed path analysis
and regression methods in S2 Appendix).
Results
The cohort consisted of 1288 subjects: 596 participants entered the study with a clinical diag-
nosis of SS that was supported by pSS AECG classification at the SRC in 378 cases (63.4%);
651 had no prior clinical SS diagnosis but 190 (29.1%) met AECG criteria for pSS, while 41 (of
which 19 [46%] were classified as pSS) were uncertain about the diagnostic impression of their
referring physician. Thus, based on our comprehensive research evaluation at the SRC, 587 par-
ticipants were classified as primary SS and 701 as non-SS sicca. The sociodemographic features
of the participants are shown in Table 1. While SS and non-SS sicca participants had similar gen-
der and ethnicity distributions, the latter were younger and less likely to be Asian (p = 9.39x10E-
06 and p = 0.007, respectively), and more likely to be Native American (p = 0.03) than subjects
classified as SS.
We observed a significant negative association between both current and previous smoking
status and SS classification. The current smoking rate among SS patients was only 4.6%, while
14.1% of non-SS sicca subjects were current smokers (p = 5.17x10E-09); these rates are in con-
trast to a SLE cohort from the same institution adjusted for age and gender,[36] in which the cur-
rent smoking rate was 18% (vs. pSS p = 1.14x10E-14 and vs. non-SS p = 0.031), or to the national
rate for women ages 45–64 of 16.8% (vs. pSS p = 4.12x10E-15 and vs. non-SS p = 0.168). [38]
Approximately 35% percent of SS patients reported ever smoking, a significantly lower propor-
tion than reported amongst the non-SS sicca controls (47%, p = 9.2x10E-06). The proportion of
subjects who were past smokers but quit was not significantly different between SS patients and
non-SS sicca participants (30% vs. 32%; p = 0.43), however, never smokers were more prevalent
amongst SS (65% vs. 53%, p = 0.0003) (Table 1). When comparing current to past smokers, the
current smokers had a significantly lower risk of being classified as SS than past smokers (OR
0.35, 95%CI 0.22–0.56, p = 3.0X10E-06, FDR q = 1.9X10E-05), and ever smokers had a lower
risk than never smokers (OR 0.61, 95%CI 0.49–0.77, p = 9.2x10E-06, FDR q = 5.83E10-05).
To determine if there were confounding factors related to the presence of chronic dryness,
we compared the overall smoking rate of our cohort (irrespective of SS classification) to com-
munity data obtained from the CDC National Health Interview Survey;[38] 9.8% of the sicca
cohort smoked in comparison to the reported rate in Oklahoma of 17.2% (p = 2.27XE-12), or
Tobacco Effects on Sjo¨gren’s Syndrome
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the national rate of 16.8% (p = 2.1X10E-11). These results support the notion that dryness,
regardless of the underlying cause, is a deterrent for smoking.
Given the large proportion of Native American patients attending our clinic and their high
smoking rates (national rate for Native American women is 32.5%),[38] we analyzed them sep-
arately and found that the overall current smoking rate of all Native American women in the
cohort was significantly lower (11.8%) than expected (p = 3.1x10E-16). Amongst Native Amer-
icans, the risk of being classified as SS for current smokers vs. past smokers, and for ever smok-
ers vs. never smokers was also significantly lower (OR = 0.34, 95%CI 0.13–0.67, p = 0.02 and
OR = 0.51, 95%CI 0.33–0.78, p = 0.002, respectively).
Detailed clinical and laboratory features of all participants based on their smoking status
and their descriptive statistics are shown in Table 2.
The most significant differences were identified when comparing objective measures of
autoimmunity (namely, autoantibody presence and focal lymphocytic sialadenitis) between
smokers and non-smokers (Table 3). Current smokers had a lower risk for presence of antiRo/
SSA (OR 0.36, 95%CI 0.20–0.64, p = 0.0004, FDR q = 0.002), hypergammaglobulinemia (OR
0.17, 95% CI 0.05–0.55, p = 0.0008, FDR q = 0.003) and, most notably, for MSG biopsy with a
focus score1 (OR 0.22, 95%CI 0.13–0.39, p = 7.54x10E-09, FDR q = 1.43x10E-07). These
Table 1. Sociodemographic characteristics and smoking status of study participants with primary Sjo¨gren’s syndrome and non-Sjo¨gren’s sicca.
Primary Sjo¨gren’s Syndrome Non-Sjo¨gren’s sicca P value
n = 587 n = 701
Age (median years [IQR]) 56 [47–65] 52 [43–62] 9.39E-06a
Gender (female) 547 (93.2%) 643 (91.7%) 0.32b
Raced
White 401 (68.3%) 442 (63.1%) 0.05c
Native Americane 148 (25.2%) 216 (30.8%) 0.03c
African American 16 (2.7%) 25 (3.6%) 0.43c
Asian 14 (2.4%) 4 (0.01%) 0.007c
Ethnicity (non-Hispanic) 559 (95.2%) 680 (97%) 0.13b
Smoking status
Current smoker 27 (4.6%) 99 (14.1%) 5.17E-09b
Past smoker 179 (30.5%) 230 (32.8%) 0.37b
Ever smoked 206 (35.1%) 329 (46.9%) 9.20E-06b
Never smoked 381 (64.9%) 372 (53.1%) 0.0003b
Smoking duration (median years [IQR]) 15 [6.75–27] 19 [10–30] 0.0013a
Cessation (median years [IQR]) 18 [7.5–30] 16 [5–28] 0.3789a
Education
12 years or less 156 (26.6%) 192 (27.5%) 0.97a
College or equivalent 298 (50.8%) 353 (50.6%) 1.0a
Graduate/Professional or more 121 (20.6%) 150 (21.5%) 0.97a
Income (median USD [IQR]) 50,486 [41,422–65,871] 49,560 [40,471–62,707] 0.08a
BMI (median [IQR]) 27.95 [23.47-33-38] 27.62 [16.06–33.28] 0.98a
a Mann-Whitney Test
b χ2 Test
c Fisher’s exact test
dSome data-points were not available; the percentages are calculated based on the subjects with data recorded.
eNative-American: Self-referred as either “Native-American” or “More than one race, one of which was Native-American”
BMI: Body Mass Index
doi:10.1371/journal.pone.0170249.t001
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protective effects of smoking were consistent when comparing ever vs. never smoking. Ever
smokers were less likely to be anti-Ro/SSA positive (OR 0.57, 95%CI 0.44–0.73, p = 4.47Ex10-
06, FDR q = 5.82x10E-05), anti-La/SSB positive (OR 0.52, 95%CI 0.39–0.70, p = 6.13x10E-06,
FDR q = 5.82x10E-05), and focus score1 (OR 0.65, 95%CI 0.52–0.83, p = 0.0005 FDR
q = 0.002). However, no significant differences were encountered in mean ESSDAI or ESSPRI
scores or their individual domains between the different smoking behaviors (data not shown).
More detailed analysis of the effects of smoking on the histopathologic patterns observed in
the MSG biopsy, revealed that current smokers had a lower frequency of focal lymphocytic sia-
ladenitis (OR 0.26, 95%CI 0.15–0.44, p = 1.60x10E-07, FDR q = 1.52x10E-06) but significantly
Table 2. Sociodemographic, clinical, and serological features of all study participants (irrespective of Sjo¨gren’s classification) based on smoking
status.
Current Smoker Past Smoker Ever Smoked Never Smoked
n = 126 n = 409 n = 535 n = 753
Age (median years [IQR]) 47 [41–55] 57 [48–66] 54 [45–63] 55 [44–63]
Gender (female) 112 (89%) 375 (92%) 487 (91%) 703 (93%)
Smoking duration (median years [IQR]) 29.25 [20–36] 15 [6–27] 19 [8–30.5] N/A
Sjo¨gren’s Syndromea 27 (21%) 179 (44%) 206 (39%) 381 (51%)
Subjective dry eyes 123 (98%) 392 (96%) 515 (96%) 720 (96%)
Subjective dry mouth 123 (98%) 397 (97%) 520 (92%) 733 (97%)
Schirmer’s (+) 40 (33%)b 157 (39%)b 197 (38%)b 284 (38%)b
Schirmer’s mm/5min (median [IQR]) 10 [5–23.5] 8 [3–15] 8 [4–16] 8 [3–17]
WUSF (+) 60 (48%)b 226 (56%)b 286 (54%)b 409 (55%)b
WUSF mL/15min (median [IQR]) 1.62 [0.7–3.13] 1.26 [0.41–2.9] 1.32 [0.45–3.0] 1.29 [0.42–2.86]
vBS (+) 51 (43%)b 169 (44%)b 220 (43%)b 327 (46%)
vB score (median [IQR]) 3 [1–5] 3 [1–5] 3 [1–5] 3 [1–5]
Auto-antibodies
Anti-Ro/SSA 15 (12%) 112 (27%) 127 (24%) 266 (35%)
Anti-La/SSB 12 (10%) 66 (16%) 78 (15%) 185 (25%)
ANA 86 (68%) 261 (64%) 347 (65%) 509 (68%)
Rheumatoid Factor 14 (11%) 83 (21%) 97 (18%) 164 (22%)
Histopathology
Focus score1 17 (14%)b 158 (42%)b 175 (35%)b 309 (46%)b
Focus score (mean±SD) 0.31±1.04 1.40±2.23 1.12±2.04 1.54±2.38
Focal lymphocytic sialadenitis 19 (17%)b 142 (44%)b 161 (37%)b 274 (46%)b
Non-specific chronic inflammation 79 (71%)b 152 (48%)b 231 (54%)b 283 (47%)b
Sclerosing chronic sialadenitis 3 (3%)b 10 (3%)b 13 (3%)b 12 (2%)b
Normal salivary gland 10 (9%)b 16 (5%)b 26 (6%)b 27 (5%)b
Serologic abnormalities
Leukopenia 5 (4%) 24 (6%) 29 (5%) 69 (9%)
Hypergammaglobulinemia (IgG) 3 (2%) 52 (13%) 55 (10%) 103 (14%)
Low C3 2 (2%) 5 (1%) 7 (1%) 21 (3%)
Low C4 5 (4%) 22 (5%) 27 (5%) 34 (5%)
ESSDAI score (mean±SD) 2.91±4.18b 3.51±5.46b 3.37±5.18b 2.97±4.34b
ESSPRI score (mean±SD) 6.69±1.94b 6.84±1.65b 6.79±1.72b 6.25±2.21b
aSjo¨gren’s Syndrome: Subjects are classified as primary Sjo¨gren’s Syndrome based on the AECG criteria.[24]
WUSF: Whole Unstimulated Salivary Flow; vBS: van Bijsterveld Score.
b Some datapoints were not available; the percentages are calculated based on the subjects with data recorded.
doi:10.1371/journal.pone.0170249.t002
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more non-specific chronic inflammation in the gland than past smokers (OR 2.73, 95%CI
1.71–4.35, p = 8.59x10E-06, FDR q = 4.08x10E-05). These differences were still present but to
a lesser degree when comparing ever to never smokers (Table 3). The proportion of MSG biop-
sies with sclerosing chronic sialadenitis or normal salivary gland tissue was similar across all
groups and so was the frequency of germinal center-like structures, atrophy, fibrosis, or fatty
infiltration of the glands (data not shown).
Participants with confirmed SS were affected by their smoking status in similar ways to the
effects identified in the complete cohort. Namely, current smokers had significantly lower
rates of minor salivary gland lip biopsies with focus score1 (p = 0.0009), focal lymphocytic
sialadenitis (p = 0.0084), and of hypergammaglobulinemia (p = 0.048), while they had higher
rates of non-specific chronic inflammation (p = 8.59x10E-06). Similarly, current smokers had
low rates of positive biopsy results when compared to never smokers (p = 0.0095) and higher
frequency of non-specific chronic inflammation (p = 0.027) (Table 4)
In an effort to control for confounding factors, we used logistic regression and two Path
Analysis (PA) models (Fig 1, Table 5 and S2 Appendix) to determine whether the path coeffi-
cient from smoking duration to SS was significant after controlling for socioeconomic status
(SES) and body mass index (BMI) as potential confounders. In both instances, smoking dura-
tion was independently protective (p = 2.93Ex10-05 and p = 2.33Ex10-05, respectively). In
other words, the longer individuals smoke, the less likely they are to be diagnosed with SS,
regardless of their SES or BMI. Similarly, controlling for caffeine and alcohol intake using a
Table 3. Risk of classification as Sjo¨gren’s syndrome and presence of associated disease criteria and histopathologic patterns based on smoking
status.
Current Smokers vs. Past Smokers Ever Smokers vs. Never Smokers
OR (95%CI) χ2 P value FDR adjusted q value OR (95%CI) χ2 P value FDR adjusted q value
Clinical and Serological features
Sjo¨gren’s Syndromea 0.35 (0.22–0.56) 3.0E10-06 1.9E10-05 0.61 (0.49–0.77) 9.2E10-06 5.83E-05
Subjective dry eyes 1.8 (0.51–6.17) 0.36 0.53 1.18 (0.67–2.08) 0.57 0.722
Subjective dry mouth 1.24 (0.34–4.46) 0.74 0.823 0.95 (0.48–1.87) 0.87 0.87
Schirmer’s (+) 0.76 (0.49–1.15) 0.18 0.311 0.97 (0.77–1.22) 0.76 0.802
vBS (+) 0.95 (0.63–1.44) 0.82 0.823 0.92 (0.73–1.15) 0.46 0.624
WUSF (+) 0.75 (0.50–1.12) 0.16 0.304 0.96 (0.77–1.21) 0.75 0.802
Anti-Ro/SSA (+) 0.36 (0.20–0.64) 0.0004 0.002 0.57 (0.44–0.73) 4.47E10-06 5.82E-05
Anti-La/SSB (+) 0.55 (0.28–1.05) 0.07 0.166 0.52 (0.39–0.70) 6.13E10-06 5.82E-05
ANA (+) 1.22 (0.79–1.87) 0.36 0.526 0.88 (0.70–1.12) 0.31 0.491
Rheumatoid factor (+) 0.53 (0.30–0.93) 0.02 0.054 0.89 (0.68–1.17) 0.42 0.614
Focus score1 0.22 (0.13–0.39) 7.54E10-09 1.43E-07 0.65 (0.52–0.83) 0.0005 0.002
Leukopenia (+) 0.66 (0.25–1.78) 0.41 0.556 0.57 (0.36–0.89) 0.013 0.041
Hypergammaglobulinemia (+) 0.17 (0.05–0.55) 0.0008 0.003 0.72 (0.51–1.02) 0.07 0.148
Low C3 (+) 1.30 (0.25–6.80) 0.75 0.823 0.46 (0.20–1.10) 0.07 0.148
Low C4 (+) 0.73 (0.27–1.96) 0.53 0.67 1.12 (0.67–1.89) 0.66 0.784
Histopathologic patterns
Focal lymphocytic sialadenitis 0.26 (0.15–0.44) 1.6E10-07 1.52E10-06 0.70 (0.55–0.91) 0.006 0.023
Non-specific chronic inflammation 2.73 (1.71–4.35) 8.59E10-06 4.08E-05 1.88 (1.0–1.65) 0.05 0.136
Sclerosing chronic sialadenitis 0.86 (0.23–3.19) 0.823 0.823 1.52 (0.68–3.36) 0.301 0.491
Normal salivary gland 1.88 (.83–4.28) 0.126 0.266 1.35 (0.78–2.35) 0.289 0.491
aSjo¨gren’s Syndrome: Subjects are classified as primary Sjo¨gren’s Syndrome based on the AECG criteria[24].
WUSF: Whole Unstimulated Salivary Flow; vBS: van Bijsterveld Score. Bolded items are statistically significant.
doi:10.1371/journal.pone.0170249.t003
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logistic regression model showed that smoking duration was independently protective from SS
classification (p = 3.58Ex10-05). A similar analysis of the effect of time since smoking cessation
on SS risk did not demonstrate a significant or independent effect.
Current smoking has a higher impact on SS classification than duration of smoking. The
odds ratio for Sjo¨gren’s syndrome classification in current smokers compared to never smok-
ers is 0.27 (95% CI 0.17–0.42; p = 6.31x10E-10) and 0.35 (95% CI 0.22–0.56; p = 3.0x10E-06)
Table 4. Sociodemographic, clinical, and serological features of study participants with primary Sjo¨gren’s Syndromea based on their smoking
status.
Current Past Ever Never
Smoker Smoker Smoked Smoked
n = 27 n = 179 n = 206 n = 381
Age (median years [IQR]) 54 [44–58] 58 [49–66] 57 [49–66] 56 [46–65]
Gender (female) 23 (85%) 162 (91%) 185 (90%) 362 (95%)*
Smoking duration (median years [IQR]) 27 [18–35] 14 [6–25] 17 [8–30] N/A
Subjective dry eyes 27 (100%) 175 (98%) 202 (98%) 376 (99%)
Subjective dry mouth 27 (100%) 177 (99%) 204 (99%) 379 (99%)
Schirmer’s (+) 14 (54%)§ 96 (55%)§ 110 (55%)§ 195 (53%)§
Schirmer’s mm/5min (median [IQR]) 5 [3–12] 5 [3–10] 5 [3–10] 5 [2–12]
WUSF (+) 15 (58%)§ 124 (70%)§ 139 (68%)§ 259 (69%)§
WUSF mL/15min (median [IQR]) 1.33 [0.4–2.95] 0.92 [0.20–2.13] 0.96 [0.25–2.28] 0.88 [0.24–2.21]
vBS (+) 12 (50%)§ 94 (58%)§ 106 (57%)§ 231 (65%)
vB score (median [IQR]) 3.5 [2–6.75] 4 [1–7] 4 [1–7] 4 [2–7]
Auto-antibodies
Anti-Ro/SSA 14 (52%) 104 (58%) 118 (57%) 237 (62%)
Anti-La/SSB 10 (37%) 58 (32%) 68 (33%) 163 (43%)
ANA 22 (82%) 141 (79%) 164 (80%) 317 (83%)
Rheumatoid Factor 7 (26%) 65 (36%)§ 72 (35%)§ 132 (35%)
Histopathology
Focus score1 15 (60%)§ 137 (87%)§*** 152 (83%)§** 266 (82%)§**
Focus score (mean±SD) 1.47±2.11 3.06±2.62** 2.85±2.61** 2.87±2.70**
Focal lymphocytic sialadenitis 11 (58%)§ 105 (85%)§** 116 (82%)§* 216 (77%)§
Non-specific chronic inflammation 7 (37%)§ 16 (13%)§**** 23 (17%)§* 47 (18%)§*
Sclerosing chronic sialadenitis 0 (0%)§ 2 (2%)§ 2 (1%)§ 6 (2%)§
Normal salivary gland 1 (5%)§ 1 (1%)§ 2 (1%)§ 6 (2%)§
Serologic abnormalities
Leukopenia 4 (15%) 16 (9%) 20 (10%) 49 (13%)
Hypergammaglobulinemia (IgG) 2 (7%) 45 (25%)* 47 (23%) 91 (24%)
Low C3 0 (0%) 3 (2%) 3 (2%) 12 (3%)
Low C4 2 (7%) 14 (8%) 16 (8%) 27 (7%)
ESSDAI score (mean±SD) 2.69±4.31§ 3.33±5.20§ 3.24±5.07§ 3.02±4.11§
ESSPRI score (mean±SD) 6.75±0.96§ 6.93±1.75§ 6.90±1.66§ 6.03±2.25§
aSjo¨gren’s Syndrome: Subjects are classified as primary Sjo¨gren’s Syndrome based on the AECG criteria.
WUSF: Whole unstimulated salivary flow; vBS: van Bijsterveld Score.
§Some datapoints were not available; the percentages are calculated based on the subjects with data recorded.
* p<0.05
**p<0.005
***p<0.0005
****p<0.0001.
doi:10.1371/journal.pone.0170249.t004
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in comparison to past smokers. The protective effect diminishes after cessation, so past smok-
ers have an OR of 0.80 (95% CI 0.60–0.97; p = 0.026). In the case of smoking duration, the
socioeconomic regression model shows that longer smoking duration results in an OR of Sjo¨g-
ren’s classification of 0.979 (95% CI 0.970–0.989; p = 2.93E-05) and the outcome of the BMI
model shows and OR of 0.977 (95% CI 0.966–0.987; p = 2.33E-05). These effects are signifi-
cantly different with non-overlapping 95%CI. (Fig 1 and S1 Appendix and S2 Appendix).
Discussion
We explored the smoking behavior of a large cohort of patients with sicca syndrome and iden-
tified a strong protective effect of tobacco smoking against disease classification as primary SS
and objective measures of autoimmunity. This effect persisted after correction for multiple
testing and was consistently observed when comparing current to past smoking, and ever to
Fig 1. Path analysis model used to estimate the effect of smoking duration on SS and the role of potential confounding factors. The standardized
path coefficients, significant odds ratios (OR) and p-values (in bold) are shown next to each path. A. Effect of smoking duration on SS, conditional on
socioeconomic status; B. Model used to estimate the effect of smoking duration on SS, conditional on body mass index.
doi:10.1371/journal.pone.0170249.g001
Table 5. Logistic Regression models exploring the effect of covariates of smoking on the risk of classification as Sjo¨gren’s Syndrome. The only
significant predictor was smoking duration.
Smoking Duration
Estimate Std Error z value P value
Model 1:
Smoking Duration -0.02 0.01 -4.16 3.14xE10-05
Education -0.03 0.02 -1.21 ns
Income 0.00 0.00 1.73 ns
Model 2:
Smoking Duration -0.02 0.01 -4.23 2.33xE10-05
BMI 0.00 0.01 0.11 ns
Model 3:
Smoking Duration -0.02 0.004 -4.09 4.3xE10-05
Alcohol intake -0.06 0.06 -0.93 ns
Caffeinated beverages -0.08 0.16 -0.47 ns
BMI: Body Mass Index.
doi:10.1371/journal.pone.0170249.t005
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never smoking. Exposure to tobacco smoke has been associated with a large number of delete-
rious effects on health. It is a well-known modulator of inflammatory and immune mecha-
nisms and its use has been associated with an increase in disease risk, severity and flares of
rheumatic diseases, in particular rheumatoid arthritis.[7, 8, 12–15] However, the precedent set
by ulcerative colitis, Behc¸et’s disease, and aphthous stomatitis[16, 20] raises the possibility of a
protective effect of smoking upon the development of some immune-mediated disorders. Few
other studies have focused on the role of tobacco in Sjo¨gren’s syndrome, which is a natural
model to explore given that smoking has also been positively associated with oral and salivary
gland diseases and symptoms of dry eyes.[40, 41]
The mechanism for the observed negative association between the classification of SS and
tobacco use remains to be determined. Our results support the notion that the protective effect
of smoking decreases after cessation since past smokers have intermediate rates of SS classifica-
tion in comparison to current and never smokers; furthermore, current smoking was a signifi-
cantly stronger determinant of SS risk than the total duration of smoking. The similar past
smoking rates in the SS and non-SS sicca groups suggest that there is not an intrinsic differ-
ence between the groups regarding confounding factors that are associated with tobacco smok-
ing. We performed a detailed analysis of known covariates of smoking, including SES,
education, income, BMI, and alcohol and caffeine intake, and none of them were independent
predictors of Sjo¨gren’s classification. The overall current smoking rate of the cohort, irrespec-
tive of classification as SS or non-SS sicca, was significantly lower than expected based on the
community smoking rates, even when adjusting for age, race, and gender. Given that the past
smoking rates of the cohort as a whole are similar to the population rates, the low current
smoking can only be explained by an increase in smoking cessation. A plausible explanation is
that the mucosal drying and irritation caused by smoking are an effective deterrent in patients
suffering from dryness.[42] This is further supported by the observed lower current smoking
rate among non-SS sicca patients compared to the SLE and community comparison groups,
despite similar past smoking rates.
The effects of tobacco on SS manifestations were confined to measures of objective autoim-
munity. The proportion of study participants that reported subjective dry eyes and dry mouth
was comparable between SS and non-SS sicca subjects, and also across all smoking behaviors.
Furthermore, there were no significant differences in objective measures of lacrimal and sali-
vary production between smokers and non-smokers. Previous studies have suggested that the
main ocular surface effects of tobacco smoking are associated with abnormal tear breakup
time rather than aqueous tear production;[40] this is likely the reason for the lack of associa-
tion of smoking status with the Schirmer’s and ocular surface staining tests. Smoking has been
associated with contradictory effects on salivary flow rate; in healthy patients, the short-term
effect is increased saliva production that eventually leads to decreased salivary flow rate.[43]
Neither our study nor earlier studies in SS patients have found significant effects of tobacco on
whole unstimulated salivary flow.[31]
The most significant negative association of smoking was with a focus score1 and with
focal lymphocytic sialadenitis on the MSG biopsy; the mean focus score of smokers was also
lower but did not reach statistical significance. These differences were observed when compar-
ing current smoking to past, ever and/or never smokers. A previous study of SS patients had
similar findings to our results, confirming lower MSG biopsy focus scores amongst current
smokers albeit a detailed analysis of histopathologic features of the biopsies was not discussed.
[31] Our results show not only that smokers are less likely to present with focal lymphocytic
sialadenitis and focus scores1, but also that they have significantly more non-specific
chronic inflammation. These results suggest that the exposure to tobacco smoke protects
against the formation of organized lymphocytic infiltrates in the salivary gland. The
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characteristic focal lymphocytic infiltrates in the exocrine glands of SS patients consist pre-
dominantly of activated CD4+ T lymphocytes (>75%) with B cells appearing in later stages of
the disease.[44] The salivary gland pathology is mainly Th-1 mediated, particularly in cases
with high focus scores, while activation of IL-17 secreting T-cells in the SS infiltrates promote
the formation of germinal centers.[45, 46] Studies have shown that smoking causes a dose-
dependent decrease in the number of CD4+ T cells, and that T cells from smokers proliferate
poorly in response to T-cell mitogens.[47] Nicotine blocks pro-inflammatory cytokines with
notable effects on IL-6, TH1, and IL-17-mediated responses.[48] Furthermore, chronic expo-
sure to benzo[a]pyrene, an important component of cigarette smoke, results in decreases in
the mass and cellularity of lymphoid tissues.[49]
When the exposure to cigarette smoke is sustained, a chronic inflammatory process is trig-
gered that promotes enhanced microbial colonization and infection, persistence of apoptotic
material and abnormal processing of cellular debris, with the potential to induce the architec-
tural remodeling characteristic of chronic inflammation[50]. Several studies have shown that
nicotine alters the morphology of salivary gland tissue. A study of parotid glands of rats
exposed to nicotine in drinking water, demonstrated atrophy and swelling of acinary cells with
an increase in the total intraacinar secretory granulae[51]; furthermore, smoke-exposed glands
exhibit enlarged intercalated and striated ductal portions[52]. Additional cigarette-smoke
effects are the dysregulation of innate immune responses in the oral cavity by modifying local
TLR expression, distribution, and activation[53], thus promoting an environment permissive
for chronic inflammation[54, 55]. So while tobacco has local inflammatory effects, its immu-
nomodulatory mechanisms may underlie the reduced organized lymphocytic infiltration of
the salivary gland observed in smoker SS patients and the preponderance on chronic non-spe-
cific inflammation.
In addition to the local exocrine gland pathology, patients with SS have alterations in the
neuroendocrine system including the hypothalamus-pituitary-adrenal axis (HPA), the hypo-
thalamic-pituitary-gonadal axis and the autonomic nervous system.[56] The HPA and auto-
nomic nervous systems modulate local and systemic immune responses through nicotinic
receptors in the brain, while non-neuronal nicotinic acetylcholine and cholinergic receptors in
the periphery have been shown to modulate the Th17 response in CD4+ T lymphocytes[57].
Nicotine has been used experimentally in the management of ulcerative colitis, endometriosis,
and sarcoidosis, but well-founded concerns about nicotine’s detrimental long-term and addic-
tive effects have limited its therapeutic applications[10]. The exploration of alternative and
selective nicotinic receptor agonists may lead to novel therapeutic options for the treatment of
inflammatory and autoimmune disorders, including Sjo¨gren’s Syndrome.
The presence of autoantibodies against Ro/SSA and La/SSB are characteristic of SS; the
overall rate of anti-Ro/SSA(+) and anti-La/SSB(+) in our cohort is 31% and 20%, respectively
(61% and 40% in SS patients). This is in contrast with the significantly lower 12% anti-Ro/SSA
(+) and 10% anti-La/SSB amongst current smokers. We did not observe any significant differ-
ences in the proportion of positive ANA and rheumatoid factor (RF). As is the case with sali-
vary flow rates, the relationship between smoking and autoantibodies has historically been
contradictory (Table 6). Long-term smoking significantly reduces serum levels of immuno-
globulins in humans but may increase the levels of some autoantibodies, in particular ANA.
[10] Decreased prevalence of anti-Ro/SSA antibodies amongst patients with SS had been
reported by Bartoloni et al[26] and of both antiRo/SSA and anti-La/SSB by Manthorpe et al.;
[31] however, the study by Karabulut only found a positive association of current smoking
with elevated ANA[29]. The results are also inconsistent in other autoimmune disorders.
Some studies of SLE patients demonstrated an increased expression of anti-dsDNA antibodies
amongst smokers [58] while other investigators did not find a clear association between
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smoking status and individual autoantibodies.[37] In the case of RA patients, smoking has
been associated with increased ANA positivity in men and RF in women.[59, 60] These seem-
ingly opposite results suggest that the role of smoking on pathogenic autoantibodies differs
from one autoimmune disease to another and may be a good example of gene-environment
interaction.
The effects of tobacco have been shown to be proportional to lifetime exposure, so that for-
mer smokers have intermediate levels of disease features associated with tobacco in compari-
son to current and never smokers.[3] Measures of exposure include smoking duration, time
since cessation, and intensity of smoking. Unfortunately, the smoking data collected in our study
does not allow us to measure the intensity of smoking, measured as pack-per-year, so the dose-
response analysis was limited to duration of exposure rather than the dosage of tar and nicotine
as potential factors influencing our results. Similarly, we did not take into account other tobacco
delivery systems that may influence the doses of each chemical; it has been reported that high
levels of tar and nicotine induce immunosuppression faster and possibly for longer time than
cigarette smoke with lower levels.[10] Animal models treated with nicotine were immunosup-
pressed for several weeks after cessation; similarly, patients with ulcerative colitis remained
relapse free for several months after the end of nicotine treatment[10]. The effect of cessation
was not replicated in our study, possibly because the vast majority of ever smokers discontinued
smoking long before being diagnosed with either SS or non-SS. However, duration of smoking
was significantly and inversely correlated with SS classification; to rule out that this was a
Table 6. Studies on the association between smoking and Sjo¨gren’s Syndrome
Author Study Population Study Objective Effects of tobacco smoking Ref
Stone et al 587 pSSa Prevalence of smoking in SS and association
of smoking habits with clinical features and
risk of SS
Lower prevalence of pSS Current
study701 non-SS sicca USA single center Lower frequency of FS1
1242 SLE Lower prevalence of focal
lymphocytic sialadenitis
981 unaffected first-degree relatives
and 946 healthy controls from USA
LFRR registry
Higher prevalence of non-specific
chronic inflammation of minor salivary
glands
Lower frequency of anti-Ro/SSA +
Lower frequency of anti-La/SSB +
Inverse correlation between smoking
duration and SS risk
Bartoloni
et al
788 pSSa from 5 Italian centers Compare prevalence of traditional
cardiovascular disease risk factors and over
disease
Lower frequency of anti-Ro/SSA + (26)
4774 control females from Registry of
Italian General Population
Lower frequency of anti-La/SSB +
Lower prevalence of pSS
Nilsson et al 51 pSSa Malmo¨, Sweden Prevalence of COPD with pSS and its
association with cigarette smoking
Increased risk of COPD in pSS even
amongst non-smokers
(27)
186 control females from Uppsala
general health survey
Manthorpe
et al
355 pSSa Malmo¨, Sweden Correlation of smoking habits with focus score
in lower lip biopsies, serum antibodies and IgG
Lower frequency of FS1 (31)
35 stomatitis sicca Lower frequency of anti-Ro/SSA +
3700 age and sex matched controls
from general population
Lower frequency of anti-La/SSB +
Karabulut
et al
207 pSSa Turkey Frequency of smoking in pSS and correlation
with autoantibodies and extraglandular
manifestations
Lower current smoking in pSS (29)
602 gender matched healthy controls Higher past or never smoking in pSS
Higher frequency of ANA +
aSubjects are classified as primary Sjo¨gren’s Syndrome based on the AECG criteria31
doi:10.1371/journal.pone.0170249.t006
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spurious effect, we controlled for potential confounding factors by detailed multivariate analyses
[39] and confirmed that smoking duration was an independent effect.
While we are aware of the significant limitations of a cross-sectional observational study
like ours, we are encouraged by the solidity of our preliminary findings. Any probabilistic
causal association between tobacco and SS would have to survive scrutiny for temporal rela-
tionship, biological plausibility, consistency with other independent studies, elimination of
confounding factors, dose-response relationship, strength of association and cessation of
effects[61, 62]. Our data support most of these factors, with the underlying biological mecha-
nisms being the least explored but most attractive area of future exploration. Designing a pro-
spective, longitudinal study of those at high risk for developing SS may shed light on the
nature of the negative association with tobacco smoking and pinpointing the chemicals within
the tobacco smoke responsible for the protective effects could open new avenues for under-
standing physiopathogenic pathways and potential therapeutic targets.
However, it is of the upmost importance to highlight that given the overwhelming negative
effect of tobacco use on health, smoking cessation should be recommended to patients with
Sjo¨gren’s syndrome who are already at higher risk for malignancy, pulmonary and cardiovas-
cular disease.
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